Login / Signup

Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.

Mario FruschelliMarco CapozzoliMaria Chiara GelmiGianni MasiPasquale Annunziata
Published in: International ophthalmology (2018)
In our cohort, therapy with fingolimod did not cause any change in CFT and TMV in MS patients during a 12-month follow-up independent of previous ON.
Keyphrases
  • multiple sclerosis
  • white matter
  • ejection fraction
  • cross sectional
  • patient reported outcomes
  • systemic lupus erythematosus
  • smoking cessation